ClinicalTrials.gg
CompletedNCT01765478Updated May 18, 2015

Safety,PK/PD, Food Effect Study of Orally Administered HM71224 in Healthy Adult Male Volunteers

A Phase 1 interventional study of HM71224 single ascending dose and HM71224 food effect in Rheumatoid Arthritis, sponsored by Hanmi Pharmaceutical Company Limited. Completed at 1 site in Netherlands. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-05-18.

Sponsored by Hanmi Pharmaceutical Company Limited · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 154 studies in Arthritis, Rheumatoid with a site in Netherlands — 17 open to participants now, 26 under way, 1 of them phase 3. Arthritis, Rheumatoid · Netherlands.

Planned enrollment
89th of 130
62 · median 150
Started
2013
with 11 others
Phase 1
17 of 154
2 open now
Registered
83rd of 154
by date

Among the 154 studies in Arthritis, Rheumatoid with a site in Netherlands, this one is the 89th largest by planned enrollment of the 130 interventional ones that give a count, is one of 12 that started in 2013, is one of 17 in phase 1, and was the 83rd registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

17 of the 154 studies in Arthritis, Rheumatoid with a site in Netherlands are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 65 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 154 studies in Arthritis, Rheumatoid with a site in Netherlands, or all of them as a file.
02

Study summary

HM71224 is a potent small molecule inhibitor of Bruton's tyrosine kinase (BTK). BTK is a member of the Tec family of non-receptor protein tyrosine kinases. BTK is mostly expressed in hematopoietic cells such as B cells, mast cells and macrophages. BTK plays key roles in multiple cell signaling pathways including B-Cell Receptor (BCR) and Fc receptor (FcR) signaling cascades and is an essential mediator not only in B-cell dependent but also in myeloid cell dependent inflammatory arthritis. HM71224 has been selected as a novel therapeutic agent for the treatment of autoimmune diseases such as rheumatoid arthritis (RA).

In view of the above, further development of HM71224 for the treatment of RA is warranted. In this first-in-man (FIM) study, a single and multiple dose escalation design will be employed, in which the primary objective is to evaluate the safety and tolerability of the compound. The biomarkers included as pharmacodynamic (PD) variables are chosen as they are indicators for any effects of HM71224 on the expected mode of action (pBTK, pPLCγ, and pERK).

Read the detailed description

Primary objective

  • To evaluate the safety and tolerability, and if possible maximum tolerated dose (MTD) of HM71224 after single and multiple ascending dose administration in healthy subjects.

Secondary objective

  • To determine the PK of HM71224 and selected metabolites (M1 and M2) following single and multiple oral dose administration of HM71224.
  • To assess the PD effects of HM71224 on the biomarkers pBTK, pPLCγ, and pERK.
  • To assess whether the PK of HM71224 is affected by food.
03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Gender : male
  2. Age : 18-65 years, inclusive
  3. : 18.5 - 30.0 kg/m2
  4. Ability and willingness to abstain from alcohol, methylxanthine-containing beverages or food (coffee, tea, cola, chocolate, energy drinks), and grapefruit (juice) from 48 h prior to entry in the clinical research center until discharge
  5. Medical history without major pathology
  6. Normal resting supine blood pressures and pulse rate, showing no deviations as judged by the MI
  7. Computerized (12-lead) (ECG) recording without signs of clinically relevant pathology or showing no clinically relevant deviations as judged by the MI
  8. Willingness to use adequate from the time of dosing until 90 days after the follow-up visit
  9. All values for hematology and for clinical chemistry tests of blood and urine within the normal range or showing no clinically relevant deviations as judged by the MI
  10. Willingness to sign the written Form (ICF)

Exclusion criteria

Exclusion Criteria:

  1. Previous participation in the current study
  2. Evidence of pathology
  3. Mental handicap
  4. History of relevant drug and/or food allergies
  5. Regular/routine treatment with non-topical medications within 30 days prior to entry into the clinical research center
  6. Use of tobacco products within 60 days prior to drug administration
  7. History of alcohol abuse or drug addiction (including soft drugs like cannabis products)
  8. Use of concomitant medication, except for acetaminophen (paracetamol), which is allowed up to 3 days before entry into the clinical research center. Multivitamins and vitamin C are allowed up to 7 days before entry into the clinical research center. All other medication (including over the counter medication, health supplements, and herbal remedies such as St. John's Wort extract) must have been stopped at least 14 days prior to entry into the clinical research center. The use of a limited amount of acetaminophen during the study is permitted.
  9. Participation in a drug study within 60 days prior to drug administration. Participation in more than 3 other drug studies in the 10 months preceding the start of this study (this is the first administration of study drug).
  10. Donation of more than 50 mL of blood within 60 days prior to drug administration. Donation of more than 1.5 liters of blood in the 10 months preceding the start of this study (this is the first administration of study drug).
  11. Positive drug screen (opiates, methadone, cocaine, amphetamines, cannabinoids, barbiturates, benzodiazepines, and alcohol)
  12. Intake of more than 24 units of alcohol per week (one unit of alcohol equals approximately 250 mL of beer, 100 mL of wine or 35 mL of spirits)
  13. Positive screen on Surface Antigen (HBsAg), anti- Virus (HCV) or anti- (HIV) 1/2
  14. Illness within 5 days prior to the first drug administration
  15. Non-willingness to consume the FDA breakfast (Part B only)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
62 participants (estimated)

Study arms

  • Experimental
    Treatment A Period 2

    40mg HM71224 single dose

    Drug: HM71224 single ascending dose

  • Experimental
    Treatment B Period1

    20mg HM71224 single dose

    Drug: HM71224 single ascending dose

  • Experimental
    Treatment A Period1

    10mg HM71224 single dose

    Drug: HM71224 single ascending dose

  • Experimental
    Treatment B Period2

    80mg HM71224 single dose

    Drug: HM71224 single ascending dose

  • Experimental
    TreatmentA Period3

    160mg HM71224 single dose

    Drug: HM71224 single ascending dose

  • Experimental
    TreatmentB Period3

    200mg HM71224 single dose

    Drug: HM71224 single ascending dose

  • Experimental
    Food effect period1

    active 4subjects + placebo 4subjects

    Drug: HM71224 food effect

  • Experimental
    Food effect period2

    active 4subjects + placebo 4subjects

    Drug: HM71224 food effect

  • Experimental
    TreatmentC

    HM71224 Xmg multiple dose for 14days

    Drug: HM71224 Multiple ascending dose

  • Experimental
    TreatmentD

    HM71224 Ymg 14days multiple dose

    Drug: HM71224 Multiple ascending dose

  • Experimental
    TreatmentE

    HM71224 Zmg 14days multiple dose

    Drug: HM71224 Multiple ascending dose

06

What researchers measure

Primary outcomes

  1. To investigate safety and tolerability

    Number of participants with AE occurrence, clinically significant clinical lab,vital sign, and/or ECG change.

    Time frame: 3days

Secondary outcomes

  1. To determine plasma PK parameters

    Cmax, C trough, tmax, kel, t1/2, AUC, CL/F, Vz, Rac, Ae, CLr, Fe% of HM71224 and selected metabolites M1, M2 following single and multiple oral dose administration of HM71224

    Time frame: 3days

  2. To determine urine PK parameters

    Cmax, C trough, tmax, kel, t1/2, AUC, %AUC, CL/F, Vz, Rac, Ae, CLr, Fe% of of HM71224 and selected metabolites M1, M2 following single and multiple oral dose administration of HM71224

    Time frame: 3days

07

Study locations

1 site
  • PRA Clinical research center
    Zuidlaren, Netherlands
08

References and documents

Publications

  • Byun JY, Koh YT, Jang SY, Witcher JW, Chan JR, Pustilnik A, Daniels MJ, Kim YH, Suh KH, Linnik MD, Lee YM. Target modulation and pharmacokinetics/pharmacodynamics translation of the BTK inhibitor poseltinib for model-informed phase II dose selection. Sci Rep. 2021 Sep 21;11(1):18671. doi: 10.1038/s41598-021-98255-7. PubMed 34548595 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2013, a primary completion of Nov 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2013
First posted
Jan 10, 2013
Start
Jan 2013
Primary completionActual
Nov 2014
CompletionActual
Nov 2014
Last update
May 18, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01765478
Responsible party
Sponsor
First posted
Jan 10, 2013
Start date
Jan 2013
Primary completion
Nov 2014
Completion
Nov 2014
Last update
May 18, 2015

Study contacts

Salah Hadi, MD MSc
principal investigator · PRA Health Sciences

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Poseltinib

Start the discussion